Clorox offers an asymmetric recovery profile as Purell, ERP normalization and margin repair support re-rating from a depressed 15.5x P/E.
Overview
Clorox is a 112-year-old branded consumer-products company with four segments—Health and Wellness, Household, Lifestyle and International—and $6.72 billion of FY26 net sales. Its portfolio spans household disinfectants, Glad bags, Kingsford, Fresh Step, Brita, Hidden Valley, Burt’s Bees and the newly acquired Purell business. **The core investment case rests on brand leadership and an operational recovery rather than on high structural growth:** approximately 80% of sales come from No. 1 or No. 2 brands, while the ERP disruption and 2023 cyberattack have created a depressed earnings base. FY26 sales declined 5%, adjusted EPS fell 28% to $5.53, and Q4 gross margin fell 520 basis points to 41.3%, but Q4 sales and adjusted EPS modestly beat consensus. Management’s FY27 outlook calls for 13% to 14% sales growth, 3.5% to 4.5% organic growth and adjusted EPS of $5.70 to $6.00, above the $5.52 consensus. **Valuation is supportive at 15.5x trailing P/E versus a 23.4x five-year average and Church & Dwight at 32x.** Key catalysts are CEO succession, $50 million of GOJO synergies, ERP normalization and deleveraging; the main offsets are 4.1x net leverage, private-label pressure and execution risk.